Evidence map›Paper›PMID 41940347›Full record

ArticleiScience2026

CGM23 corresponds to a pan-coronavirus lipopeptide inhibitor potently inhibiting virion fusion.

Yusuke Matsui, Roland Schwarzer, Mauricio Montano, Ekram W Helmy, Rahul K Suryawanshi, Taha Y Taha, Yan Wang, Yvonne Angel, Marc Adler, M Flori Sassano and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in iScience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Yusuke MatsuiGladstone Infectious Disease Institute, Gladstone Institutes, San Francisco, CA 94158, USA.
Roland SchwarzerGladstone Infectious Disease Institute, Gladstone Institutes, San Francisco, CA 94158, USA.
Mauricio MontanoGladstone Infectious Disease Institute, Gladstone Institutes, San Francisco, CA 94158, USA.
Ekram W HelmyGladstone Infectious Disease Institute, Gladstone Institutes, San Francisco, CA 94158, USA.
Rahul K SuryawanshiGladstone Infectious Disease Institute, Gladstone Institutes, San Francisco, CA 94158, USA.
Taha Y TahaGladstone Infectious Disease Institute, Gladstone Institutes, San Francisco, CA 94158, USA.
Yan WangChemPartner Co., South San Francisco, CA 94080, USA.
Yvonne AngelChemPartner Co., South San Francisco, CA 94080, USA.
Marc AdlerChemPartner Co., South San Francisco, CA 94080, USA.
M Flori SassanoDepartment of Internal Medicine, University of Kansas Medical Center, Kansas City, KS 66160, USA.
Hyunil JoDepartment of Pharmaceutical Chemistry, University of California, San Francisco, San Francisco, CA 94158, USA.
Robert TarranDepartment of Internal Medicine, University of Kansas Medical Center, Kansas City, KS 66160, USA.
Melanie OttGladstone Infectious Disease Institute, Gladstone Institutes, San Francisco, CA 94158, USA.
Warner C GreeneGladstone Infectious Disease Institute, Gladstone Institutes, San Francisco, CA 94158, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We developed a pan-coronavirus lipopeptide fusion inhibitor, CGM23, which binds to the highly conserved spike heptad repeat-1 domain, thus interrupting the formation of the six-helix bundle required for membrane fusion.

Indexed as

BiochemistryPharmacologyVirology

Identifiers

PMID41940347
PMCPMC13049657

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.